|
|
We are a biopharmaceutical company focused on in-licensing, developing
and commercializing novel therapies for the treatment of
cancer. We currently have two clinical-stage oncology product
candidates. Our lead product
candidate, Asentar™ (DN-101), is in a Phase 3 clinical trial for
the treatment of androgen-independent prostate cancer, or
AIPC, also known as hormone-refractory prostate cancer. Our
second product candidate, AQ4N, is being investigated in combination
with radiation and chemotherapy in a Phase 1/2 clinical trial of patients with newly diagnosed glioblastoma multiforme.
Our highly experienced team uses its expertise in oncology product development to identify, license and develop novel therapeutics with the potential to improve clinical outcomes for cancer patients. We also seek to develop anti-cancer agents that may reduce the toxicities associated with current treatments. In addition, we attempt to mitigate development risks by licensing product candidates with well-characterized mechanisms of action and supportive pre-clinical or clinical data. We believe that our oncology development expertise enables our team to design efficient clinical development and commercialization programs that could provide cancer patients with improved treatment options over current standards of care.
|
|
 |
|
